Advanced Solid Tumors
Conditions
Brief summary
To evaluate the incidence of adverse events (AEs), serious adverse events (SAEs), AEs meeting protocol-defined dose limiting toxicity (DLT) criteria, AEs leading to discontinuation, and death up to safety follow-up visit occurs.
Detailed description
To include a summary of the exposure levels of the study drug up to the last pharmacokinetics sampling time point., To evaluate the overall response rate (ORR) up to last tumor assessments until disease progression or death.
Interventions
DRUGBMS986482
DRUGBEVACIZUMAB
Sponsors
Bristol-Myers Squibb Services Unlimited Company
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the incidence of adverse events (AEs), serious adverse events (SAEs), AEs meeting protocol-defined dose limiting toxicity (DLT) criteria, AEs leading to discontinuation, and death up to safety follow-up visit occurs. | — |
Secondary
| Measure | Time frame |
|---|---|
| To include a summary of the exposure levels of the study drug up to the last pharmacokinetics sampling time point., To evaluate the overall response rate (ORR) up to last tumor assessments until disease progression or death. | — |
Countries
Belgium, Denmark, France, Greece, Italy, Netherlands, Spain, Sweden
Outcome results
None listed